OOppenheimer MMicrosoft · MSFT

Oppenheimer Reiterates Outperform on Microsoft, $515 PT

Jul 22, 2026· 1 min read· Reproduced verbatim
Rating
Buy
Price target
$515
Previous
Implied upside
+29%

Oppenheimer analyst Brian Schwartz reiterated an Outperform rating and $515 price target on Microsoft (NASDAQ: MSFT).

“We maintain our Outperform rating on MSFT ahead of F4Q26 results.

In our view, Microsoft’s demand appears healthy, F4Q should show a robust AI business and stable M365 revenue growth, and investor expectations are not elevated after IBM’s negative preannouncement and multiples re-rating lower in F4Q26.

These items should be enough to support the stock post F4Q.

However, investor concerns over Capex growth and returns, AI disruption to the M365 franchise, increasing competitive pressures, and perception that management is playing catch-up in the AI market are unlikely to be resolved post the F4Q update.

The Street may also be modeling Microsoft’s Capex too optimistically as the company needs to continue investing in elevated Capex growth in FY27 for greater AI and cloud capacity over the medium term.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.